【摘要】 心血管疾病是2型糖尿病最常见的并发症，代谢综合征所致的高血糖、高血脂、高血压和肥胖等危险因素共同促进冠状动脉粥样硬化的发生与进展。新型降糖药物胰高血糖素样肽-1受体激动剂（GLP-1RA）在降低血糖、改善胰岛功能的同时，还能减轻体重、降低血压、调节血脂、抑制炎症并改善血管内皮功能等多重效应，从而显著降低糖尿病患者的心血管事件风险，且大量循证研究已证实其心血管保护作用。本文旨在综述GLP-1 RA在心血管保护中的作用机制及最新研究进展，并探讨其在心血管疾病防治中的应用前景。更多还原

【Abstract】 Cardiovascular disease is the most common complication of type 2 diabetes. Risk factors such as hyperglycemia, dyslipidemia, hypertension and obesity associated with metabolic syndrome collectively promote the onset and progression of coronary atherosclerosis. The novel hypoglycemic agent glucagon-like peptide-1(GLP-1) receptor agonist not only lowers blood glucose and improves pancreatic function but also reduces body weight, lowers blood pressure, regulates lipids, suppresses inflammation and enhances vascular endothelial function. Consequently, it significantly reduces the risk of cardiovascular events in diabetic patients,with extensive evidence-based research confirming its cardiovascular protective effects. This article aims to review the mechanisms of the action and recent research advances of GLP-1 receptor agonist in cardiovascular protection,and explore their application prospects in the prevention and treatment of cardiovascular diseases.更多还原